The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
Abstract
Purpose: Bendamustine HCl is a bifunctional mechlorethamine derivative with clinical activity in the treatment of non-Hodgkin's lymphoma. This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab. Patients and Methods: Patients received rituximab 375 mg/m 2 intravenously on day 1 and bendamustine 90 mg/m 2 intravenously on days 2 and 3 of each 28-day cycle for four to six cycles. An additional dose of rituximab was administered 1 week before the first cycle and 4 weeks after the last cycle. Sixty-six patients (median age, 60 years) received at least one dose of both drugs. Results: Overall response rate was 92% (41% complete response, 14% unconfirmed complete response, and 38% partial response). Median duration of response was 21 months (95% CI, 18 to 24 months). Median progression-free survival time was 23 months (95% CI, 20 to 26 months). Outcomes were similar for patients with indolent or mantle cell histologies. The combination was generally well tolerated; the primary toxicity was myelosuppression (grade 3 or 4 neutropenia, 36%; grade 3 or 4 thrombocytopenia, 9%). Conclusion: Bendamustine plus rituximab is an active combination in patients with relapsed indolent and mantle cell lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationHiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 651
van Oers, M. H. J., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., van't Veer, M., Vranovsky, A., Holte, H., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021113 · Cited by 592
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Rummel, M. J., Al-Batran, S. E., Kim, S.-Z., Welslau, M., Hecker, R., Kofahl-Krause, D., Josten, K.-M., Dürk, H., Rost, A., Neise, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.100 · Cited by 441
New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M., & Miller, T. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1674 · Cited by 375
Leoni, L. M., Bailey, B., Reifert, J., Bendall, H. H., Zeller, R. W., Corbeil, J., Elliott, G., & Niemeyer, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1061 · Cited by 368
Schulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk152 · Cited by 362
Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., & Greco, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.191 · Cited by 330
Friedberg, J. W., Cohen, P., Chen, L., Robinson, K. S., Forero-Torres, A., La Casce, A. S., Fayad, L. E., Bessudo, A., Camacho, E. S., Williams, M. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5070 · Cited by 296
Self-citation(2001) · PubMed · Cited by 279
Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D., & Goris, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.040 · Cited by 258
Chow, K. U., Sommerlad, W. D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M., Hoelzer, D. F., Mitrou, P. S., & Weidmann, E. (2002) · PubMed · Cited by 185
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines
Strumberg, D., Harstrick, A., Doll, K., Hoffmann, B., & Seeber, S. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199606000-00007 · Cited by 153
Biology and therapy of mantle cell lymphoma
Williams, M. E., & Densmore, J. J. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000174039.69656.2b · Cited by 44
Self-citation
Cited by
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Self-citationSehn, L. H., Chua, N., Mayer, J., Dueck, G., Trněný, M., Bouabdallah, K., Fowler, N., Delwail, V., Press, O., Salles, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30097-3 · Cited by 349
Self-citationWang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Follicular lymphoma: 2020 update on diagnosis and management
Freedman, A., & Jacobsen, E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25696 · Cited by 268
Metadata
- Authors
- Robinson, K. S., Williams, M. E., van der Jagt, R. H., Cohen, P., Herst, J. A., Tulpule, A., Schwartzberg, L. S., Lemieux, B., & Cheson, B. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-09-20
- Volume
- 26
- Issue
- 27
- Pages
- 4473-4479
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120755425
- Cited by
- 353
- References
- 19
- FWCI
- 22.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.